Global Platelet-Rich Plasma Therapy Market, By Source (Autologous, Allogenic), Application (Orthopedic, Dermatology, Cardiac Muscle Injury), Product (Pure-PRP, Leukocyte-Rich, Leukocyte-Rich Fibrin)– Industry Trends and Forecast to 2029
Market Analysis and Size
Blood is used to make platelet-rich plasma (PRP). It is created by centrifuging human blood and extracting platelet-rich plasma, which has a higher concentration of platelets than normal. Platelets aid in blood clotting and speed up the healing of tendons, muscles, and ligaments. PRP is used in a variety of procedures, including tendon repair and rotator cuff augmentation. Platelets are rich in healing agents and connective tissue formation.
Data Bridge Market Research analyses that the platelet-rich plasma therapy market which was USD 537.85 million in 2021, would rocket up to USD 1426.81 million by 2029, and is expected to undergo a CAGR of 12.97% during the forecast period 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Source (Autologous, Allogenic), Application (Orthopedic, Dermatology, Cardiac Muscle Injury), Product (Pure-PRP, Leukocyte-Rich, Leukocyte-Rich Fibrin)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Harvest Technology (U.S), DePuy Synthes (U.S), Stryker (U.S), Zimmer Biomet (U.S), Arthrex Inc. (U.S), Terumo BCT Inc. (U.S), Celling BioSciences Inc. (U.S), APEX Biologix (U.S), Juventix Regenerative Medical, LLC (Italy), Dr. PRP USA LLC (U.S), Ycellbio Medical Co., Ltd. (South korea), EmCyte Corporation (U.S), Regen Lab SA (Switzerland), ISTO technologies II, Inc. (U.S), Cision US Inc (U.S), Weigao group (China)
|
|
Market Opportunities
|
|
Market Definition
Platelet-rich plasma therapy is a sort of regenerative medicine that can increase the natural growth factors your body utilises to mend tissue.
Platelet-Rich Plasma Therapy Market Dynamics
Drivers
- Growing need for plasma therapy
The growing need for plasma therapy in therapeutic sectors, as well as the latest technological technologies and the highly beneficial results of pure PRP therapy, are all driving the platelet-rich plasma therapy market forward. In the anticipated period of 2022-2029, modernization and technical improvements in plasma therapy machines will generate more chances for the platelet-rich plasma therapy market.
- Emerging platelet-rich plasma (PRP) therapy utilized for various applications
Platelet-rich plasma therapy is a promising new treatment option for a variety of conditions. Because of its increased use in cosmetic procedures, platelet-rich plasma therapy has recently become more widely used in clinical settings. Dermatologists and plastic surgeons also use the natural healing properties of platelet-rich plasma to improve the appearance and health of the skin. Its use in face rejuvenation has also shown to be beneficial. Pure platelet-rich plasma is also employed for its advantages, which include faster tissue development and repair, faster healing, and improved overall performance. Platelet Rich Plasma is also projected to grow swiftly because to fewer side effects and a lower risk of immunological and allergic reactions. As a result of the foregoing statements, the market is likely to grow throughout the forecast period.
Opportunities
PRP has been widely used in clinical settings in recent years. In the realm of cosmetic surgery, it has gained a lot of traction. The natural healing qualities of platelets are being used by plastic surgeons and dermatologists to improve the appearance and overall health of the skin. Several research studies have looked at the use of platelet rich plasma for face rejuvenation and found that it has excellent aesthetic outcomes.
Restraints/Challenges
Rising price volatility in platelet-rich plasma therapy and weak reimbursement policies in wound care devices are among the primary factors acting as constraints, which will pose a significant challenge to the platelet-rich plasma therapy market's growth throughout the forecast period.
This platelet-rich plasma therapy market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the platelet-rich plasma therapy market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Covid-19 Impact on Platelet- Rich Plasma Therapy Market
The pandemic of COVID-19 had a good effect on the market. There are no specific antiviral drugs that can be used to treat it. Coronavirus infection is known to cause thromboembolic consequences (COVID-19). COVID-19, on the other hand, has been associated to platelet disregulation. Increased basal platelet activation and reduced platelet responses were linked to a worse result in COVID-19. Platelet-rich plasma therapy was utilised to treat coronavirus as a result of the covid-19 outbreak because platelets play a critical role in preventing respiratory disorders and maintaining lung function, and the need for platelet-rich plasma therapy has increased dramatically.
Recent Development
- In February 2020, EmCyte has finalised the acquisition of Cellmedix Holdings LLC, acquiring all of the latter's assets, including its proprietary product system, the Centrepid Platelet Concentrator.
Global Platelet- Rich Plasma Therapy Market Scope
The platelet-rich plasma therapy market is segmented on the basis of type, application and source. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Source
- Autologous
- Allogenic
Type
- Pure PRP
- Leucocyte-rich PRP
- Leukocyte-rich Fibrin (L-PRF)
Application
- Orthopedic
- Darmatology
- Cardiac Muscle Injury
- Muscle Injury
- Others
Platelet- Rich Plasma Therapy Market Regional Analysis/Insights
The platelet-rich plasma therapy market is analysed and market size insights and trends are provided by country, type, application and source as referenced above.
The countries covered in the platelet-rich plasma therapy market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the platelet-rich plasma therapy market because of the increasing number of people suffering from orthopedic disorders.
The platelet-rich plasma therapy market is expected to grow in Asia-Pacific region during the forecast period of 2022 to 2029.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Platelet Rich Plasma Therapy Market Share Analysis
The platelet-rich plasma therapy market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to platelet-rich plasma therapy market.
Some of the major players operating in the platelet-rich plasma therapy market are:
- Harvest Technology (U.S)
- DePuy Synthes (U.S)
- Stryker (U.S)
- Zimmer Biomet (U.S)
- Arthrex Inc. (U.S)
- Terumo BCT Inc. (U.S)
- Celling BioSciences Inc. (U.S)
- APEX Biologix (U.S)
- Juventix Regenerative Medical, LLC (Italy)
- Dr. PRP USA LLC (U.S)
- Ycellbio Medical Co., Ltd. (South Korea)
- EmCyte Corporation (U.S)
- Regen Lab SA (Switzerland)
- ISTO technologies II, Inc. (U.S)
- Cision US Inc (U.S)
- Weigao group (China)
SKU-